COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact
Abstract Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2eab7a70fea74c65a94d95d63fb05ed5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2eab7a70fea74c65a94d95d63fb05ed5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2eab7a70fea74c65a94d95d63fb05ed52021-12-02T16:24:59ZCOVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact10.1038/s41598-021-94719-y2045-2322https://doaj.org/article/2eab7a70fea74c65a94d95d63fb05ed52021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94719-yhttps://doaj.org/toc/2045-2322Abstract Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and compare the population impact of vaccines with different efficacy profiles (VESYMP and VESUSC) satisfying licensure criteria. We developed a mathematical model of SARS-CoV-2 transmission, calibrated to data from King County, Washington. Rollout scenarios starting December 2020 were simulated with combinations of VESUSC and VESYMP resulting in up to 100% VEDIS. We assumed no reduction of infectivity upon infection conditional on presence of symptoms. Proportions of cumulative infections, hospitalizations and deaths prevented over 1 year from vaccination start are reported. Rollouts of 1 M vaccinations (5000 daily) using vaccines with 50% VEDIS are projected to prevent 23–46% of infections and 31–46% of deaths over 1 year. In comparison, vaccines with 90% VEDIS are projected to prevent 37–64% of infections and 46–64% of deaths over 1 year. In both cases, there is a greater reduction if VEDIS is mediated mostly by VESUSC. The use of a “symptom reducing” vaccine will require twice as many people vaccinated than a “susceptibility reducing” vaccine with the same 90% VEDIS to prevent 50% of the infections and death over 1 year. Delaying the start of the vaccination by 3 months decreases the expected population impact by more than 50%. Vaccines which prevent COVID-19 disease but not SARS-CoV-2 infection, and thereby shift symptomatic infections to asymptomatic infections, will prevent fewer infections and require larger and faster vaccination rollouts to have population impact, compared to vaccines that reduce susceptibility to infection. If uncontrolled transmission across the U.S. continues, then expected vaccination in Spring 2021 will provide only limited benefit.David A. SwanChloe BracisHolly JanesMia MooreLaura MatrajtDaniel B. ReevesEileen BurnsDeborah DonnellMyron S. CohenJoshua T. SchifferDobromir DimitrovNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q David A. Swan Chloe Bracis Holly Janes Mia Moore Laura Matrajt Daniel B. Reeves Eileen Burns Deborah Donnell Myron S. Cohen Joshua T. Schiffer Dobromir Dimitrov COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| description |
Abstract Trial results for two COVID-19 vaccines suggest at least 90% efficacy against symptomatic disease (VEDIS). It remains unknown whether this efficacy is mediated by lowering SARS-CoV-2 infection susceptibility (VESUSC) or development of symptoms after infection (VESYMP). We aim to assess and compare the population impact of vaccines with different efficacy profiles (VESYMP and VESUSC) satisfying licensure criteria. We developed a mathematical model of SARS-CoV-2 transmission, calibrated to data from King County, Washington. Rollout scenarios starting December 2020 were simulated with combinations of VESUSC and VESYMP resulting in up to 100% VEDIS. We assumed no reduction of infectivity upon infection conditional on presence of symptoms. Proportions of cumulative infections, hospitalizations and deaths prevented over 1 year from vaccination start are reported. Rollouts of 1 M vaccinations (5000 daily) using vaccines with 50% VEDIS are projected to prevent 23–46% of infections and 31–46% of deaths over 1 year. In comparison, vaccines with 90% VEDIS are projected to prevent 37–64% of infections and 46–64% of deaths over 1 year. In both cases, there is a greater reduction if VEDIS is mediated mostly by VESUSC. The use of a “symptom reducing” vaccine will require twice as many people vaccinated than a “susceptibility reducing” vaccine with the same 90% VEDIS to prevent 50% of the infections and death over 1 year. Delaying the start of the vaccination by 3 months decreases the expected population impact by more than 50%. Vaccines which prevent COVID-19 disease but not SARS-CoV-2 infection, and thereby shift symptomatic infections to asymptomatic infections, will prevent fewer infections and require larger and faster vaccination rollouts to have population impact, compared to vaccines that reduce susceptibility to infection. If uncontrolled transmission across the U.S. continues, then expected vaccination in Spring 2021 will provide only limited benefit. |
| format |
article |
| author |
David A. Swan Chloe Bracis Holly Janes Mia Moore Laura Matrajt Daniel B. Reeves Eileen Burns Deborah Donnell Myron S. Cohen Joshua T. Schiffer Dobromir Dimitrov |
| author_facet |
David A. Swan Chloe Bracis Holly Janes Mia Moore Laura Matrajt Daniel B. Reeves Eileen Burns Deborah Donnell Myron S. Cohen Joshua T. Schiffer Dobromir Dimitrov |
| author_sort |
David A. Swan |
| title |
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| title_short |
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| title_full |
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| title_fullStr |
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| title_full_unstemmed |
COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| title_sort |
covid-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/2eab7a70fea74c65a94d95d63fb05ed5 |
| work_keys_str_mv |
AT davidaswan covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT chloebracis covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT hollyjanes covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT miamoore covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT lauramatrajt covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT danielbreeves covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT eileenburns covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT deborahdonnell covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT myronscohen covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT joshuatschiffer covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact AT dobromirdimitrov covid19vaccinesthatreducesymptomsbutdonotblockinfectionneedhighercoverageandfasterrollouttoachievepopulationimpact |
| _version_ |
1718384041927901184 |